Literature DB >> 22767536

Mitral valve involvement as a predominant feature of cardiac amyloidosis.

Girish Viswanathan1, James Williams, Simon Slinn, Philip Campbell.   

Abstract

Cardiac involvement in systemic amyloidosis carries poor prognosis with a median survival of 5 months.(1) The authors report an unusual presentation of cardiac amyloidosis in the form of predominant mitral regurgitation. The patient responded very well to medical therapy with subsequent improvement of mitral valve dysfunction. The authors would like to highlight this multisystem involvement and the presence of a complex overlap of systemic features.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22767536      PMCID: PMC3038029          DOI: 10.1136/bcr.08.2008.0821

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

Review 1.  Ethnic distribution of amyloidosis: an autopsy study.

Authors:  F S Buck; M N Koss; A E Sherrod; A Wu; M Takahashi
Journal:  Mod Pathol       Date:  1989-07       Impact factor: 7.842

2.  Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement.

Authors:  Blaithnead Murtagh; Stephen C Hammill; Morie A Gertz; Robert A Kyle; A Jamil Tajik; Martha Grogan
Journal:  Am J Cardiol       Date:  2005-02-15       Impact factor: 2.778

Review 3.  Diagnosis and management of the cardiac amyloidoses.

Authors:  Rodney H Falk
Journal:  Circulation       Date:  2005-09-27       Impact factor: 29.690

4.  The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement.

Authors:  S W Dubrey; K Cha; J Anderson; B Chamarthi; J Reisinger; M Skinner; R H Falk
Journal:  QJM       Date:  1998-02

5.  Cardiac amyloidosis presenting as severe mitral regurgitation.

Authors:  R S Engelmeier; J B O'Connell; R Subramanian
Journal:  Int J Cardiol       Date:  1983-10       Impact factor: 4.164

6.  Cardiovascular magnetic resonance in cardiac amyloidosis.

Authors:  Alicia Maria Maceira; Jayshree Joshi; Sanjay Kumar Prasad; James Charles Moon; Enrica Perugini; Idris Harding; Mary Noelle Sheppard; Philip Alexander Poole-Wilson; Philip Nigel Hawkins; Dudley John Pennell
Journal:  Circulation       Date:  2005-01-03       Impact factor: 29.690

7.  M-mode and two-dimensional echocardiographic features in cardiac amyloidosis.

Authors:  A G Siqueira-Filho; C L Cunha; A J Tajik; J B Seward; T T Schattenberg; E R Giuliani
Journal:  Circulation       Date:  1981-01       Impact factor: 29.690

8.  Severe mitral regurgitation due to cardiac amyloidosis--a rare reason for ruptured chordae.

Authors:  Hiroyuki Nishi; Masataka Mitsuno; Masaaki Ryomoto; Yuji Miyamoto
Journal:  Interact Cardiovasc Thorac Surg       Date:  2008-08-28

9.  Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis.

Authors:  Ashutosh D Wechalekar; Hugh J B Goodman; Helen J Lachmann; Mark Offer; Philip N Hawkins; Julian D Gillmore
Journal:  Blood       Date:  2006-09-21       Impact factor: 22.113

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.